Lupin advances on the buzz of receiving USFDA approval for anti-diabetes drug

20 Jul 2015 Evaluate

Lupin is currently trading at Rs. 1978.50, up by 3.90 points or 0.20% from its previous closing of Rs. 1974.60 on the BSE.

The scrip opened at Rs. 1980.00 and has touched a high and low of Rs. 1984.50 and Rs. 1967.00 respectively. So far 15811 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2112.00 on 08-Apr-2015 and a 52 week low of Rs. 1071.90 on 21-Jul-2014.

Last one week high and low of the scrip stood at Rs. 1984.90 and Rs. 1866.95 respectively. The current market cap of the company is Rs. 89119.94 crore.

The promoters holding in the company stood at 46.59% while Institutions and Non-Institutions held 43.57% and 9.84% respectively.

Pharma Major Lupin, has reportedly received an approval from the USFDA for PrandiMet (also known as Prandin) generic, which is used for treatment of type 2 diabetes. The product is expected to have sales of $200-$300 million in the US. Danish pharma company Novo Nordisk is the innovator of the drug that has been approved to lower blood glucose in adult patients.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.


Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×